Navigation Links
Asymmetrex Article for Parent’s Guide to Cord Blood Describes New Solution for the Stem Cell Counting Problem

On January 15 of this year, the Parents’ Guide to Cord Blood website featured an invited news article by Asymmetrex director James L. Sherley, M.D., Ph.D. The PGCB was founded by former physicist Dr. Frances Verter, who now runs cell therapy resources like the PGCB and Now in its 21st year of operation, the PGCB continues its mission to educate parents with accurate and balanced information about cord blood banking, medical therapies, and cord blood storage options.

In his news article, Sherley takes the opportunity to share with parents, who store cord blood from their babies for future use in medical treatments, information about the newest advance in stem cell medicine. This advance made by Asymmetrex and its partner company, AlphaSTAR Corporation, is quite relevant to cord blood storage and use for medical treatments.

Working together the two companies devised a computer simulation approach to solve the stem cell counting problem. The new technology could be used to determine the dose of therapeutic stem cells in stored cord blood samples for the first time. Such knowledge would address presently intractable problems in cord blood transplant medicine, like identifying the high fraction of stem cell-deficient cord blood samples before they fail a patient.

The PGCB education opportunity fits well within Asymmetrex’s ongoing campaign to increase awareness to the half century-old stem cell counting problem. Asymmetrex’s new advance, introduced into the stem cell medicine industry two years ago, is the first, and still the only, solution for the stem cell counting problem.

Since the introduction of Asymmetrex’s AlphaSTEM Test™ for specific and accurate counting of therapeutic tissue stem cells, the company’s market research made it quite clear that the stem cell counting problem was quite insidious, with many in the industry being unaware or uncertain of it and the medical deficiencies it causes. Asymmetrex’s response has been to increase awareness to the problem, including among patients; and in the case of kids, their parents.

Frances Verter’s invitation supports Asymmetrex’s education effort. "Arguably the most important question in stem cell medicine is how to accurately measure the doses of therapies, and now Asymmetrex proposes a solution." The news article is an important effort towards bringing this crucial information to the full awareness of patients, as they can be quite effective in bringing its importance to the attention of stem cell doctors.

Of course, parents are not the only subscribers to the PGCB. A wide and diverse range of the participants in stem cell medicine and the stem cell supply industry also utilize the website. Sherley observes that, “The more who know, the more and sooner our solution will be evaluated for being the new quantitative standard for therapeutic stem cells in stem cell biology and medicine. That’s our goal.”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells
2. New Commentary from Asymmetrex LLC Director Anticipates Forthcoming E-Book on “Stem Cell Genetic Fidelity”
3. Boston Stem Cell Biotech Start-up Asymmetrex Will Present Essential Technologies for Stem Cell Medical Engineering at Chicago Stem Cell Research Conference
4. Asymmetrex Opens Up 5th World Congress on Cell and Stem Cell Research in Chicago with a Focus on Its New Technologies for Stem Cell Medical Engineering
5. Asymmetrex Interviewed in Anticipation of Presentations at the 14th Annual World Preclinical Congress Focused on Tackling Translation Challenges
6. Asymmetrex Launches a Crowdsourcing Campaign to Introduce New Biomarkers for Counting Previously Elusive Tissue Stem Cells
7. In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells
8. Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June
9. Asymmetrex Introduces “The Third Dimension of Time” to 3D Cell Modelers at the 14th Annual World Preclinical Congress in Boston
10. Asymmetrex’s Crowdsourcing Campaign For Evaluating A First Biomarker for Counting Adult Tissue Stem Cells Is Gaining Momentum
11. Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer
Post Your Comments:
(Date:2/2/2019)... ... February 01, 2019 , ... ... the appointment of its new CEO, Julien Dert, being effective on February 1st, ... experience in finance and management, in which more than 12 years in the ...
(Date:1/30/2019)... (PRWEB) , ... January 29, 2019 , ... K&R Negotiations ... featured expert at a special online event titled: Six Ways to Shorten the ... eastern time, February 13, 2019 on the BrightTALK network. , Negotiation expert Kresic ...
(Date:1/28/2019)... ... January 28, 2019 , ... Fragment-based lead ... compounds. In this early stage, false positives can be problematic due to high ... vital that screening techniques are highly sensitive to detect weak interactions. Nanomed ...
(Date:1/21/2019)... ... January 21, 2019 , ... Microbial Discovery ... for the industrial and institutional cleaning market. MDG’s SporActiv liquid and powder product ... needs. Applications include odor control, floor and tile cleaners, carpets, drains, portable restroom ...
Breaking Biology Technology:
(Date:1/20/2019)... ... ... Boston-based Laboratory as a Service (LaaS) leader, Mass Innovation Labs, has changed its ... and service offerings for biotech and life sciences companies. , “Meeting the ... agile and adaptable than ever before. One that doubles-down on the things that matter ...
(Date:1/10/2019)... ... January 09, 2019 , ... Dr. Beanlands is the ... in Ottawa, Ontario, Canada. He is also Director of its National Cardiac PET ... in the Department of Radiology, and in the Department of Cellular and Molecular medicine. ...
(Date:1/8/2019)... ... January 07, 2019 , ... Join industry experts Julie ... a live webinar on Thursday, January 17, 2019 at 1pm EST. ... of risk during the clinical trial process. Featured speakers will also present a case ...
Breaking Biology News(10 mins):